Alterations in the characteristics and outcomes of acute and chronic graft-versus-host disease following post-transplant high dose cytoxan prophylaxis for haploidentical transplantation and in patients over 60 at high risk for graft-versus-host disease.
Study #: GV17-03
Study Status: Published
Presentation(s)
2020, TCT Meetings (Oral)
Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis.
Citation
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO.
Transplantation and Cellular Therapy. 2022, Oct 01: 28(10): 28(10):681-693. doi: 10.1016/j.jtct.2022.07.013. Epub 2022, Jul 17. PMCID:PMC10141544.
PubMed
PMID: 35853610
Abstract